Rizatriptan 10 mg wafers were listed on the Pharmaceutical Benefits Scheme (PBS) as authority required (streamlined) on 1 March 2010 for people with past migraines that have usually failed to respond to analgesics.1
Rizatriptan has been available overseas for more than 10 years.2 All triptans are effective for migraine3,4 but individual response cannot be predicted.5 If the first triptan fails, try another.
As of 1 April 2010, the PBS restriction for naratriptan, sumatriptan and zolmitriptan has changed: there is no longer a requirement for past migraines to have failed to respond to ergotamine*.6 This change brings the restriction into line with that of rizatriptan.
* Injectable dihydroergotamine is the only ergot alkaloid indicated for migraine listed on the PBS
